Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canagliflozin in type 2 diabetes with diabetic nephropathy (CREDENCE-like renal and CV outcomes study)
2013-004494-28Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM), diabetic glomerulosclerosis, chronic kidney disease (CKD) and 1 more comparing Canagliflozin with Placebo (2 arms). Primary endpoint: Primary composite renal endpoint. Started Feb 2014; status: completed.
02
Drugs
canagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)diabetic glomerulosclerosischronic kidney disease (CKD)cardiac morbidity
Beyond the preview
Go deeper on 2013-004494-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004494-28.